WARRINGTON, Pa., March 13, 2015 /PRNewswire/ -- Discovery
Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology
company dedicated to advancing a new standard of respiratory
critical care will host a live teleconference and webcast at
8:30 a.m. Eastern Time on
Tuesday March 17, 2015 at which time
management will discuss the 2014 fourth quarter financial results
along with other business updates.
The press release and the live webcast of the conference call
will be available via Discovery Labs' corporate website at
www.discoverylabs.com. The webcast will be made available on the
events page. An archive will be available after the call at the
same address until Tuesday March 31,
2015.
To participate in the live conference call, please dial
(888) 346-0767 (domestic) or (412)
902-4251 (international). After placing the call, please ask
to be joined into the Discovery Labs conference call. The
conference call replay number is (877) 344-7529
(domestic) or (412) 317-0088 (international); please
use 10061701 as the replay passcode.
About Discovery Labs
Discovery Laboratories, Inc. is a specialty biotechnology company
focused on advancing a new standard in respiratory critical care.
Discovery Labs' technology platforms include a novel proprietary
KL4 surfactant, a synthetic, peptide-containing surfactant that is
structurally similar to pulmonary surfactant, and proprietary drug
delivery technologies being developed to enable efficient delivery
of aerosolized KL4 surfactant. Discovery Labs' strategy is
initially focused on neonatology and improving the management of
respiratory distress syndrome (RDS) in premature infants. Discovery
Labs believes that its RDS product portfolio has the potential to
become the new standard of care for RDS and, over time, to enable
the treatment of a significantly greater number of premature
infants who could benefit from surfactant therapy but are currently
not treated. SURFAXIN® (lucinactant) Intratracheal Suspension,
Discovery Labs' first KL4 surfactant-based product, is the only
available synthetic alternative to animal derived surfactants
approved by the U.S. Food and Drug Administration (FDA). Full
prescribing information can be found at
http:///www.surfaxin.com.
For more information, please visit the company's website at
www.Discoverylabs.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/discovery-labs-to-hold-conference-call-on-tuesday-march-17-2015-to-discuss-fourth-quarter-2014-financial-results-and-other-business-updates-300050338.html
SOURCE Discovery Laboratories, Inc.